Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (221-230 of 223) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 223 results.
JCI Insight|December 22, 2025
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasisDavid Strawn, James G Krueger, Robert Bissonnette, et al.
Frontiers in Immunology|March 27, 2025
Guselkumab binding to CD64<sup>+</sup> IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signalingKacey L Sachen, Deepa Hammaker, Indra Sarabia, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
Pageof 23

Showing results (221-230 of 223) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 223 results.
JCI Insight|December 22, 2025
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasisDavid Strawn, James G Krueger, Robert Bissonnette, et al.
Frontiers in Immunology|March 27, 2025
Guselkumab binding to CD64<sup>+</sup> IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signalingKacey L Sachen, Deepa Hammaker, Indra Sarabia, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
Pageof 23